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PVulnerable Plaque
umber of Yellow Plaques
etected in a Coronary Artery Is Associated
ith Future Risk of Acute Coronary Syndrome
etection of Vulnerable Patients by Angioscopy
omohito Ohtani, MD, Yasunori Ueda, MD, PHD, FACC, FESC, Isamu Mizote, MD, Jota Oyabu, MD,
atsuki Okada, MD, Atsushi Hirayama, MD, PHD, FACC, Kazuhisa Kodama, MD, PHD, FACC
saka, Japan
OBJECTIVES We sought to test whether the risk of acute coronary syndrome (ACS) can be estimated by
angioscopy.
BACKGROUND Disruption of vulnerable plaque and subsequent thrombosis is regarded as a major mechanism
of ACS. Although yellow plaques are supposedly vulnerable, the association between
angioscopically determined extent of coronary atherosclerosis and risk of ACS events has not
been reported.
METHODS Patients (n  552) who received catheterization and angioscopic examination for the
diagnosis of coronary artery diseases were prospectively included and followed up for new onset
of ACS events. Yellow color intensities of all detected yellow plaques were graded as 1, 2, or 3
according to the standard colors. Number of yellow plaques (NYP) in a coronary artery and
maximum color grade of detected yellow plaques (maxYP) were determined. Association between
the incidence of ACS events and angioscopic findings were analyzed.
RESULTS Follow-up interval was 57.3  22.1 months. Acute coronary syndrome events were detected
in 39 patients (7.1%). Although maxYP was not statistically different (2.0 0.7 vs. 1.8 0.9;
p  0.18), NYP was higher in the patients with an ACS event than those without the event
(3.1  1.8 vs. 2.2  1.5; p  0.008). Patients with NYP 2 and those with NYP 5 had
2.2- and 3.8-fold higher event rates, respectively, than those with NYP 0 or 1 (9.0% and
15.6%, respectively, vs. 4.1%; p  0.02). Multivariate logistic regression analysis revealed
NYP and multivessel disease as the independent risk factors of ACS events.
CONCLUSIONS Patients with multiple yellow plaques per vessel have a higher risk of suffering ACS events
than those with NYP 0 or 1. Angioscopy would be useful to detect vulnerable
patients. (J Am Coll Cardiol 2006;47:2194–200) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.064Cardiology Foundation
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tathologic and angioscopic studies (1–5) have revealed that
isruption of lipid-rich yellow plaques and subsequent
hrombosis play a major role both in the development of
cute coronary syndrome (ACS) and in the asymptomatic
rogression of coronary artery diseases. Yellow color inten-
ity of plaques, which can be evaluated by angioscopy, is
nown to be determined by the thickness of fibrous cap, and
s associated with plaque vulnerability (6,7). Although it is
f great interest to find out from the whole coronary artery
rees the “vulnerable plaques” that will cause ACS in the
ear future, angioscopy or any other invasive examination
ould not be practically useful for this purpose. However,
e thought it would be beneficial to identify “vulnerable
atients” using angioscopic findings. We previously pro-
osed the hypothesis (8) on the process of yellow plaque
ormation and development of ACS. According to this
ypothesis, patients with more yellow plaques of higher
ellow color intensity would have a higher risk of suffering
From the Cardiovascular Division, Osaka Police Hospital, Osaka, Japan. Drs.
htani and Ueda contributed equally to this paper.a
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005, accepted January 9, 2006.CS. We have been prospectively following all patients
ho received angioscopic examination in our hospital since
996 to find out if the risk of suffering an ACS event can be
stimated by the angioscopic findings. Here we analyzed the
ollow-up data to October 2004 of the patients who received
ngioscopic examination from July 1996 to July 2002.
ETHODS
tudy patients and protocol. Patients who received cathe-
erization and successful angioscopic examination for the di-
gnosis of coronary artery diseases were prospectively followed
or ACS events since 1996. Although we included all the
atients who received successful angioscopic examination for
he first time, angioscopic examination was performed for the
ollowing reasons: 1) to identify and evaluate the culprit lesions
n ACS patients; 2) to evaluate the stabilization/healing of the
isrupted culprit plaques in the follow-up of ACS patients; 3)
o evaluate the percutaneous coronary intervention (PCI)
arget lesions in patients with stable effort angina or silent
yocardial ischemia; 4) to evaluate the stabilization/healing of
he PCI site in the follow-up of patients with stable effort
ngina or silent myocardial ischemia; and 5) to examine in the
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June 6, 2006:2194–200 Detection of Vulnerable Patients by Angioscopyuspected ACS patient without significant coronary stenosis if
he patient has disrupted yellow plaque and thrombus forma-
ion. Acute coronary syndrome events as the end point of this
tudy were defined as sudden cardiac death, acute myocardial
nfarction, and unstable angina that occurred after the initial
atheterization. Sudden cardiac death included all death if a
oncardiac cause was not identified. Acute myocardial infarc-
ion and unstable angina was defined as worsening or newly
nset effort angina or chest pain at rest whose cause was
dentified as the newly developed occlusion or stenosis of
oronary artery that required PCI or coronary artery bypass
raft. Differentiation of acute myocardial infarction from un-
table angina was previously done by the elevation of creatine
inase-MB and recently by the elevation of troponin T. We
ade efforts so that we would not miss any ACS event by
erforming coronary angiography in all possible ACS patients.
cute coronary syndrome due to restenosis or reocclusion of
CI site was excluded from the event. Therefore, the best
fforts were made to detect all coronary events caused by abrupt
rogression of de novo lesions probably owing to plaque
upture and thrombosis. Treatment strategies of patients were
ecided without knowing the results of angioscopic examina-
ions. A well-trained research nurse assessed the patients’
haracteristics using a structured questionnaire. Hypertensive
atients in this study were defined as those with blood pressure
140/90 mm Hg or those already taking antihypertensive
rugs. Hypercholesterolemic patients in this study were de-
ned as those with fasting serum total cholesterol220 mg/dl
r those already taking lipid-lowering drugs. Diabetic patients
ere defined as those with fasting blood glucose 126 mg/dl
r those already receiving drug therapy for diabetes mellitus.
atients were regarded as taking each drug (aspirin or statin) if
he drug was administered at any time during the follow-up
nterval. Informed written consent was obtained from all
atients. The protocol was approved by the Osaka Police
ospital Ethical Committee. For this report, patients who
eceived angioscopic examination from July 1996 to July 2002
ere included, and the ACS events documented to October
004 were analyzed. Among 581 patients included for this
tudy, 552 (95%) patients were successfully followed up. We
xamined if the baseline extent of coronary atherosclerosis
valuated by angioscopy would be associated with the inci-
ence of ACS events during the follow-up interval.
atheterization and angioscopic examination. Catheter-
zation was performed by femoral approach using a 6- to
-F sheath and catheters. Intravenous heparin (100 U/kg)
as administered at the beginning of catheterization. A coro-
Abbreviations and Acronyms
ACS  acute coronary syndrome
maxYP  maximum color grade of detected yellow
plaques
NYP  number of yellow plaques
PCI  percutaneous coronary interventionary angiogram was recorded by the Advantx medical system AGeneral Electric, Milwaukee, Wisconsin). The culprit vessel
ith angiographically significant (50%) stenosis was exam-
ned by angioscopy. In the patients without angiographically
ignificant stenosis, the suspected culprit vessel that had mild
r no coronary stenosis (50%) or the vessel in which
asospasm was induced by acetylcholine stress test was exam-
ned by angioscopy. Angioscopic observation was performed
rom the distal segment to the ostium of the vessel as far as the
essel diameter was 2 mm. Angioscopic examination was
erformed before and after PCI, if needed, so that we could
bserve the whole target vessel fully. The angioscope MC-
00E (Nihon Kohden, Tokyo, Japan) and the optic fiber
S-003 (Nihon Kohden) were used. The angioscopic obser-
ations were made while blood was cleared away from view by
he injection of 3% dextran-40 as previously reported (3). The
mages of angioscopy were recorded on S-VHS and digital
ideotapes.
valuation of angioscopic images. Number of yellow
laques in the observed coronary artery and the yellow color
ntensity of those yellow plaques were evaluated. Yellow plaque
as defined simply as the yellow area on the luminal surface,
hich may have a smooth or irregular surface with or without
rotrusion into the lumen. Yellow color of those plaques was
raded as 1 (light yellow), 2 (yellow), or 3 (intense yellow)
ccording to the standard colors as previously reported (7,9). If
o yellow plaque was detected, the color grade was determined
s 0 (white). The extent of coronary atherosclerosis was
valuated for each patient by the maximum yellow color grade
maxYP) and the number of yellow plaques (NYP). We made
fforts not to miss white area in the yellow area, however
arrow it might be; and if white area was detected in the midst
f yellow area, we counted the yellow areas as separate yellow
laques. Thus, the sizes of yellow plaques were not so different
about 3 to 9 mm in length) in our study population. Angio-
copic images were interpreted by two specialists in angioscopy,
nd in case of disagreement a third reviewer determined the
valuation. There were no cases where three reviewers judged
ifferent color grades, meaning at least two of them agreed on
he judgment. Interobserver and intraobserver reproducibility
or the interpretation of plaque color was 85% and 87%,
espectively.
tatistics. Continuous data were presented as mean values
D. The incidence of ACS events was compared between
roups by chi-squared test and estimated with the Kaplan-
eier method. A log rank test was used to compare the
ncidence of ACS events between groups. Data of patients’
haracteristics were compared between groups by the Stu-
ent t test or chi-square test, and their influence on the
ncidence of ACS events was examined by multivariate
ogistic regression analysis. A p value of0.05 was regarded
s statistically significant.
ESULTS
atients’ characteristics. Among 552 patients included,
CS events were detected in 39 patients during the
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Detection of Vulnerable Patients by Angioscopy June 6, 2006:2194–200ollow-up interval of 57.3  22.1 months. Although one
atient died from noncardiac cause, cardiac sudden death
as not detected. Nonfatal acute myocardial infarction
ccurred in 17 patients and unstable angina in 22 patients.
atients’ characteristics were compared between patients
ith and without an ACS event (Table 1). Prevalence of
ypertension, hypercholesterolemia, diabetes mellitus, or
urrent smoking was not different between the groups.
revalence of multivessel disease was significantly higher in
he patients with an ACS event. Although maxYP was not
tatistically different, NYP was higher in the patients with
CS event than those without the event. Patients’ charac-
able 1. Patient Characteristics
Event Free
(n  513)
ACS Event
(n  39)
p
Value
ge, yrs 59.9  10.2 59.7  8.4 0.92
ale gender, n (%) 411 (80) 32 (84) 0.54
iagnosis at baseline, n (%)
Acute MI 267 (52) 21 (54) 0.83
On PCI 155 (30) 13 (33)
At FU* 112 (22) 8 (21)
Unstable angina 90 (18) 8 (21) 0.64
On PCI 76 (15) 8 (21)
At FU* 14 (3) 0 (0)
Stable effort angina 68 (13) 5 (13) 0.94
On PCI 53 (10) 5 (13)
At FU* 15 (3) 0 (0)
Silent myocardial ischemia 62 (12) 4 (10) 0.74
On PCI 57 (11) 3 (7)
At FU* 5 (1) 1 (3)
No coronary stenosis 50% 26 (5) 1 (3) 0.49
CI performed at baseline, n (%) 341 (67) 29 (74) 0.31
ngioscopically examined vessel,
n (%)
LAD 272 (53) 18 (46) 0.41
LCX 77 (15) 8 (21) 0.38
RCA 164 (32) 13 (33) 0.84
rior MI, n (%) 217 (42) 17 (44) 0.87
o. of diseased vessel,† n (%)
3 52 (10) 8 (21) 0.04
2 118 (23) 13 (33) 0.14
1 317 (62) 17 (44) 0.03
0 26 (5) 1 (3) 0.48
ultivessel disease,‡ n (%) 170 (33) 21 (54) 0.01
oronary risk factors, n (%)
Hypertension 268 (52) 23 (59) 0.41
Hypercholesterolemia 288 (56) 23 (59) 0.74
Diabetes mellitus 163 (31) 14 (36) 0.59
Current smoking 230 (44) 21 (54) 0.31
edications, n (%)
Aspirin 479 (93) 37 (95) 0.95
Statin 331 (65) 21 (54) 0.23
ngioscopic findings
maxYP 1.8  0.9 2.0  0.7 0.18
NYP 2.2  1.5 3.1  1.8 0.008
ata are presented as n (%) or mean SD. *Planned follow-up at 1 or 6 months after
CI. †Number of vessels with 75% diameter stenosis by angiography. ‡Multivessel
isease was defined as having 2 coronary vessels with 75% diameter stenosis by
ngiography.
ACS  acute coronary syndrome; FU  follow-up; LAD  left anterior
escending coronary artery; LCX  left circumflex coronary artery; maxYP 1
aximum yellow color grade; MI  myocardial infarction; NYP  number of yellow
laques; PCI  percutaneous coronary intervention; RCA  right coronary artery.eristics of those who suffered ACS event are further
resented in Table 2. There was no significant difference in
he time from angioscopic examination to ACS event
etween the patients with NYP 0 or 1 and those with NYP
2 (32.3  27.4 months vs. 28.4  23.4 months; p 
.71). There was no significant difference in the time from
ngioscopic examination to an ACS event between the
atients who had 50% stenosis and those who had 50%
tenosis in the future ACS culprit at baseline angiography
34.5  27.2 months vs. 27.6  23.8 months; p  0.45).
igure 1 shows the distribution of maxYP and NYP.
ultiple yellow plaques (NYP 2) were observed in 335
atients (60%), and 5 yellow plaques were observed in 45
atients (8%). A representative case with no yellow plaque
nd that with multiple yellow plaques were presented in
igure 2. The culprit lesion of ACS event had been
bserved by angioscopy at baseline only in four patients
10.3%). The yellow color grade of those lesions was 0 in no
atient, 1 in one (25%) patient, 2 in two (50%) patients, and
in one (25%) patient. A case among them was presented
n Figure 3.
isk of ACS event. According to the results of multivar-
ate logistic regression analysis (Table 3), multivessel disease
nd NYP were the independent risk factors of an ACS
vent. Presence of multiple yellow plaques was associated
ith incidence of an ACS event (log-rank 5.53; p  0.02)
Fig. 4). Patients with multiple yellow plaques (NYP 2)
ad a 2.2-fold higher incidence of an ACS event than those
ith fewer (NYP 0 or 1) yellow plaques (9.0% [30 of 335]
s. 4.1% [9 of 217]; p  0.02). Furthermore, patients with
5 yellow plaques had an extremely higher (3.8-fold)
ncidence of an ACS event than those who had no or a
ingle yellow plaque (15.6% [7 of 45] vs. 4.1% [9 of 217]; p
0.01). The use of a statin did not have significant
nfluence on the risk of ACS events by logistic regression
nalysis in the present study. However, the use of a statin
as associated with a lower incidence of an ACS event
mong patients with multiple yellow plaques (13.8% [15 of
able 2. Patient Characteristics of Those Who Suffered an
CS Event
39
ime from angioscopic examination to ACS event,
months (mean  SD)
29.3  24.1
ype of ACS event, n (%)
Acute MI 17 (44)
Unstable angina 22 (56)
ulprit vessel of ACS event, n (%)
LAD 14 (36)
LCX 12 (31)
RCA 12 (31)
LMCA 1 (2)
iameter stenosis of ACS culprit at baseline, n (%)
50% 27 (69)
50% 12 (31)
CS culprit observed by angioscopy at baseline, n (%) 4 (10)
MCA  left main coronary artery; other abbreviations as in Table 1.08] vs. 6.6% [15 of 227]; p  0.02), although it was not
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.6% [6 of 131]; p  0.41).
ISCUSSION
e have demonstrated in the present study that the number
f yellow plaques in a coronary artery and multivessel disease
re independent risk factors of an ACS event. Patients with
2 yellow plaques and those with 5 yellow plaques had a
.2- and 3.8-fold higher incidence of an ACS event,
espectively, than those with no or a single yellow plaque.
herefore, angioscopy may be useful to find patients at high
isk of an ACS event (i.e., vulnerable patients). This would
igure 1. Distributions of number of yellow plaques (NYP) (A) and maxim
ith NYP 5 comprised 60% and 9% of study patients, respectively.
igure 2. A representative case with no yellow plaque (A) and a represent
n the right coronary artery: number of yellow plaques (NYP) 0, maximum color g
n the right coronary artery: NYP 3, maxYP 3.e the first report, to our knowledge, that reveals the
ssociation between the presence of multiple yellow plaques
etermined by angioscopy and the future incidence of pure
CS events, excluding the events caused by restenosis/
eocclusion among patients with wide spectrum of coronary
rtery diseases.
lassic coronary risk factors and plaque formation. Hy-
ertension, hypercholesterolemia, diabetes mellitus, and
urrent smoking are known (10–13) to enlarge lipid-rich
oronary plaques and increase their vulnerability. However,
hose classic coronary risk factors were not selected as
ndependent risk factors of an ACS event in the present
lor grade of yellow plaques (maxYP) (B). Patients with NYP2 and those
ase with multiple yellow plaques (B). (A) No yellow plaque was detectedative c
rade of yellow plaques (maxYP) 0. (B) Three yellow plaques were detected
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Detection of Vulnerable Patients by Angioscopy June 6, 2006:2194–200tudy. Because yellow plaques are regarded as the direct
ause of an ACS event (14), classic coronary risk factors may
ork as a risk for an ACS event mainly through the
ormation of yellow plaques.
ultiple plaques and ACS events. Several reports have
evealed multiple vulnerable plaques in the patients with
oronary heart disease and have been associated with the
isk of ACS events. Presence of plaque ruptures remote
rom the culprit lesion has been shown in autopsy studies
15,16), angiography studies (17), and intravascular ultra-
ound (IVUS) studies (18–21). The presence of multiple
omplex lesions in the patients with ACS has been associ-
ted with a high incidence of subsequent cardiac events
nrelated to the initial event (17), although the ruptured
igure 3. A case in which culprit vessel of acute coronary syndrome event h
A) Initial clinical presentation when angioscopy was performed was inferio
rtery. (B) The second event was also inferior acute myocardial infarction, 51
ellow plaque had been detected. PCI  percutaneous coronary interventlaque detected by IVUS has not been associated with clinical events under statin treatment (21). Yellow plaques
re more often accompanied by thrombus and regarded as
ore vulnerable than white plaques, as we have previously
eported (7). Waxman et al. (22) have demonstrated that
ellow plaques are associated with the risk of adverse
utcomes after balloon angioplasty. These reports are con-
istent with our result that patients with multiple yellow
laques have higher risk of ACS event.
xtent of plaque formation in culprit and nonculprit
essels. The process of plaque formation is now regarded as
pan-coronary process occurring widely in three coronary
essels. Three-vessel IVUS study revealed multiple plaque
uptures in nonculprit segments of culprit and nonculprit
essels (19,20). We have previously reported using angios-
en observed by angioscopy at baseline. The patient was a 48-year-old man.
te myocardial infarction. The culprit lesion was in the distal right coronary
ths later. The culprit lesion was in the proximal right coronary artery wheread be
r acu
monopy that number of yellow plaques in a coronary artery is
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oronary arteries, suggesting that formation of yellow
laques may progress equally in three major coronary
rteries (23). Therefore, the extent of coronary atheroscle-
osis and the risk of future ACS events may be evaluated by
bserving any one of three coronary arteries.
ngioscopically determined extent of coronary athero-
clerosis. The extent of plaque formation would be mea-
ured by the area and the vulnerability of yellow plaques.
ecause vulnerability of yellow plaques could be measured
y their yellow color intensity (7), we used the maximum
ellow color grade as the marker of plaque vulnerability.
ecause we could not measure the total area of yellow
laques by angioscopy, we used the number of yellow
laques as the marker of plaque area. One of the reasons
hy maxYP was not proved to be a significant risk in the
resent study may be that it would reflect only the proba-
ility of the plaque to rupture but not necessarily the
robability of the plaque to cause ACS. It will be difficult to
nd the specific plaque that has a high probability of causing
CS, because silent plaque ruptures are often observed by
ngioscopy or IVUS and because we do not know the time
ourse of plaque formation and rupture. Because the time
ourse of yellow plaque formation and disruption is un-
nown, it is possible that coronary segments that will cause
future ACS event may not have yellow plaque at baseline.
ost yellow plaques observed at baseline may not cause an
CS event even if they disrupted (silent plaque rupture); in
ontrast, yellow plaques that caused an ACS event might be
ormed after the time of baseline angioscopic observation.
e had the information on the baseline angioscopic ap-
earance of the segments that caused an ACS event later
nly in four patients. However, we revealed in the present
tudy that vulnerable patients could be detected by the
umber of yellow plaques in a coronary artery evaluated by
ngioscopy. The vulnerability of yellow plaques may change
ithin a shorter period than the number of yellow plaques
hanges; therefore, the number of yellow plaques rather
han the vulnerability of those plaques may better reflect the
isk of an ACS event. The most important observation in
ur study is that imaging analysis would predict future risk
or cardiovascular events by the overall number of lesions
able 3. Independent Risk Factors of ACS Event by
ultivariate Logistic Regression Analysis
Adjusted Hazard Risk* (95% CI) p Value
YP 1.23 (1.03–1.45) 0.02
ultivessel disease† 2.21 (1.10–4.46) 0.03
tatin use 0.38 (0.12–1.19) 0.10
Adjusted for male gender, age, ACS at baseline, prior myocardial infarction,
ypertension, diabetes mellitus, hypercholesterolemia, current smoking, aspirin use.
Multivessel disease was defined as having 2 coronary vessels with 75% diameter
tenosis by angiography.
ACS  acute coronary syndrome; CI  confidence interval; NYP  number of
ellow plaques.ather than by identifying the most vulnerable lesions.

erevention of ACS events by lipid-lowering therapy with
tatins. Although lipid-lowering therapy with statins was
eported effective to prevent secondary cardiac events (24–
6), it was not selected by multivariate logistic regression
nalysis in this study as a factor that had significant
nfluence on the incidence of an ACS event. A possible
eason may be that our study population was small and was
ot randomized for the use of statins. Actually, the percent-
ge of statin use increased at follow-up compared with the
oint of enrollment. However, among patients with multi-
le yellow plaques, statin use was significantly associated
ith a low incidence of ACS events, whereas among
atients with no or a single yellow plaque it was not.
herefore, statin treatment may be more effective in the
atients with multiple yellow plaques. The mechanism of
tatin-induced plaque stabilization (27,28) is thought to be
change in plaque composition from large lipid core with
hin fibrous cap to small lipid core with thick fibrous cap.
ngioscopic study (29) also revealed that statin treatment
educed yellow color intensity of coronary plaques. There-
ore, angioscopy may be useful to select patients who will
eceive more benefit from statin treatment.
linical implications. We can evaluate the risk of an ACS
vent for each patient by angioscopy and change the therapy
ccording to the evaluated risk; however, its application is
imited to the relatively high-risk patients who receive
atheterization. Furthermore, we may be able to use angios-
opy to determine the surrogate end point in clinical trials to
valuate the effect of drugs that reduce the risk of ACS
vents through the regression of vulnerable plaques.
tudy limitations. Because only the patients with successful
ngioscopic examination were included in this study, results
ight not apply to the patients who had coronary arteries not
uitable for angioscopic examination (e.g., diffusely stenotic or
ortuous coronary arteries).Wemay possibly underestimate the
xtent of plaque formation in the patients who have a few but
igure 4. Incidence of acute coronary syndrome (ACS) events. The
ncidence of ACS events was estimated with the Kaplan-Meier method.
atients with multiple yellow plaques (number of yellow plaques [NYP]
2) had a significantly higher incidence (p 0.02 by log rank test) of ACS
vents compared with those with fewer yellow plaques (NYP 0 or 1).
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Detection of Vulnerable Patients by Angioscopy June 6, 2006:2194–200arge yellow plaques; however, in the real world among the
apanese population, the size of yellow plaques was not very
ifferent (about 3 to 9 mm in length) in most patients.
urthermore, large yellow plaques were exclusively detected in
he patients who had multiple yellow plaques (i.e., no patient
ad only one large yellow plaque). Therefore, the effect of this
nderestimation should be small. However, theoretically, this
s an important limitation of angioscopic evaluation and should
etter be solved by developing a new analyzing method. The
ength of observed coronary artery by angioscopy was not
easured. However, the number of yellow plaques per vessel
ay be better associated with the risk of the patient to suffer an
CS event than the number of yellow plaques per observed
essel length. Because this study was not designed to evaluate
he effect of drug interventions, interpretation on the effect of
tatins should be limited. Although we observed only one of
hree coronary arteries at baseline, based on the fact that
umber of yellow plaques was not statistically different among
hree coronary arteries, the other two coronary arteries might
ot always have similar yellow plaques. Although the data on
-reactive protein was reported to be associated with the ACS
isk, they were not available and were not included for analysis
n the present study.
onclusions. Patients with 2 yellow plaques and those
ith 5 yellow plaques have a 2.2- and 3.8-fold higher
ncidence of an ACS event, respectively, than those with a
ingle or no yellow plaque in a coronary artery. Angioscopy
ould be useful for the detection of vulnerable patients who
ave a high risk of suffering ACS events.
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